AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two
AZ announce data that it says will establish its lung cancer drug Tagrisso as standard second line treatment in patients with certain mutations. The data showed Tagrisso slowed tumour progression compared with standard chemotherapy and was also more effective in patients with brain metastases. Tagrisso is approved in second line non-small cell lung cancer with
A consortium of international pharmaceutical firms and UK universities have launched a new £40m fund for early drug research.
A three year partnership between AstraZeneca (AZ) and French National Institute of Health and Medical Research (Inserm) is aiming to advance the understanding of biological mechanisms that come with the conditions. Based on the findings, they hope to develop new therapeutic approaches to type 2 diabetes and chronic kidney disease.
cialis Xigduo, Launched in the UK” src=”http://i39.tinypic.com/hwxyt2.jpg” width=”230″ height=”80″ />Type II diabetes patients living in England and Wales have gained access to a new treatment option to improve blood glucose levels after AstraZeneca launched their diabetes drug, Xigduo, earlier this week. Xigduo combines BMS-512148 and metformin in a twice-daily tablet for use in patients inadequately
Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (BMS-512148) in adults with type 2 diabetes
AstraZeneca have reinforced their interest in China by entering into a joint venture between their biotechnology arm MedImmune, and Chinese firm WuXi AppTec, which seeks to quicken the development of a new medicine for inflammatory conditions in the country. Under the joint venture, in which the two organisations will have equal ownership, MedImmune’s experimental, fully-human
Bristol-Myers Squibb (B-MS) yesterday announced that they have completed their $5 billion purchase of Amylin and its diabetes franchise, meaning they can now progress onto a planned marketing alliance with drug giant AstraZeneca. The New York-based drug maker, who agreed to buy Amylin on the 1st July, confirmed that they have now successfully finalised their
AstraZeneca announced earlier today that a US district court has ruled that the formulation patent for its extended-release version of the antipsychotic blockbuster, Seroquel XR, is valid and has been infringed by generics companies. The court in New Jersey found the formulation patent protecting Seroquel XR (quetiapine fumarate) extended-release tablets to be valid and ruled
AstraZeneca has suffered a further obstacle in their bid to delay generic competition access to their Seroquel franchise after a lawsuit launched against the US Food and Drug Administration (FDA) concerning its stance on copies of the antipsychotic was thrown out of court. Earlier this month, the Anglo-Swedish drug maker stepped up their fight to